Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 docetaxel + ramucirumab vs docetaxel + placebo in stage IV NSCLC after platinum
jRCT2080221986Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing ramucirumab + docetaxel with docetaxel + placebo (2 arms).
02
Drugs
ramucirumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2080221986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221986.